Neuphoria Therapeutics (NEUP) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on allosteric ion channel modulators for CNS disorders with high unmet need, including PTSD and social anxiety disorder.

• Lead candidate BNC210 targets the α7 nicotinic acetylcholine receptor, showing fast onset and favorable safety in trials.

• Strategic partnership with Merck (MSD) for positive allosteric modulators in cognitive dysfunction, including Alzheimer's disease.

• Pipeline includes preclinical assets for schizophrenia, autism, and chronic pain, plus legacy oncology programs out-licensed for future value.

Financial performance and metrics

• As of December 31, 2023, cash and cash equivalents were A$14.9M (A$25.8M as adjusted for private placement proceeds).

• Net proceeds of US$7.5M from the first tranche of a private placement in June 2024.

• Accumulated losses as of December 31, 2023, were A$218.6M.

Use of proceeds and capital allocation

• Proceeds from warrant exercises (up to US$12.7M) will fund R&D, pre-commercialization, and general corporate purposes.

• Net proceeds from the private placement are allocated to advancing BNC210 registrational programs, business development, working capital, and general corporate purposes.